Bredack, C.; Edelmann, M.R.; Borroni, E.; Gobbi, L.C.; Honer, M.
Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines. Pharmaceuticals 2022, 15, 1445.
https://doi.org/10.3390/ph15121445
AMA Style
Bredack C, Edelmann MR, Borroni E, Gobbi LC, Honer M.
Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines. Pharmaceuticals. 2022; 15(12):1445.
https://doi.org/10.3390/ph15121445
Chicago/Turabian Style
Bredack, Christoph, Martin R. Edelmann, Edilio Borroni, Luca C. Gobbi, and Michael Honer.
2022. "Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines" Pharmaceuticals 15, no. 12: 1445.
https://doi.org/10.3390/ph15121445
APA Style
Bredack, C., Edelmann, M. R., Borroni, E., Gobbi, L. C., & Honer, M.
(2022). Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines. Pharmaceuticals, 15(12), 1445.
https://doi.org/10.3390/ph15121445